ARTV vs IDXX · $37.3M cap vs P/E 40, rev $2.36B
Artiva Biotherapeutics, Inc. Common Stock (ARTV) versus IDEXX Laboratories Inc (IDXX) — a side-by-side from cached financials, not a winner call.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a biotechnology company listed on US.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Latest reported ARTV revenue for 2025-12-31 was $0. Net income was -$83.9M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. ARTV currently screens at market cap $37.3M.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
ARTV currently screens at market cap $37.3M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Not investment advice. Open the ARTV and IDXX stock pages for the full models.
Not investment advice.